Monoclonal Antibodies Targeting Amyloid for Alzheimer Disease

In this interview, dementia expert Gil D. Rabinovici, MD, discusses monoclonal antibodies that target beta-amyloid–-including a recent phase 3 trial of donanemab published in JAMA-–and reviews considerations for their use in patients with Alzheimer disease.

Related Content:

Amyloid-Targeting Monoclonal Antibodies for Alzheimer Disease
https://ja.ma/45fl0b5

Donanemab in Early Symptomatic Alzheimer Disease
https://ja.ma/3DN6YBQ

Podcast was originally published on August 3, 2023.
https://edhub.ama-assn.org/jn-learnin...

---------------------------------------------------------------------------------
Follow JAMA Clinical Reviews on:

Youtube:    • JAMA Clinical Reviews  
Apple Podcasts: https://podcasts.apple.com/us/podcast...
Spotify: https://open.spotify.com/show/229VuDi...
Pocket Casts: https://pca.st/3ghw
Your podcast app of choice: https://pod.link/1027430378
Website: https://jamanetwork.com/journals/jama...

---------------------------------------------------------------------------------
For more from JAMA
• https://www.jama.com
•   / jamajournal  
•   / jama_current  
•   / jamanetwork  

Follow the JAMA Network
• https://www.jamanetwork.com
• http://www.jamanetworkaudio.com
•   / jamanetwork  
•   / jamanetwork  
•   / jamanetwork  
•   / jamanetwork